Palisade Bio (PALI) Net Margin (2011 - 2023)

Palisade Bio's (PALI) quarterly Net Margin came in at 936.0% in Q1 2023, up 99.28% on a QoQ basis from 130216.12% in Q4 2020.

Palisade Bio (PALI) Net Margin (2011 - 2023) Analysis & Trends

Palisade Bio (PALI) has 11 years of Net Margin data on file, last reported at 936.0% in Q1 2023.

On a quarterly basis, Net Margin changed N/A year-over-year to 936.0% in Q1 2023; TTM through Dec 2023 was 5076.8%, a N/A change from a year earlier, with the FY2023 full-year figure at 16808.8%, changed N/A from the prior year.
Net Margin for Q1 2023 stood at 936.0%, up from 130216.12% in the prior quarter.
Over the last five years, Net Margin for PALI reached as high as 936.0% in Q1 2023 and fell as low as 130216.12% in Q4 2020.
Historically, Net Margin has averaged 68487.43% across 3 years, with a median of 75960.88% in 2020.
On a YoY basis, Net Margin climbed as much as 5895662 bps in 2020 and fell as far as 5154577 bps in 2020.
Year by year, Net Margin stood at 84976.44% in 2019, then slumped by 53 bps to 130216.12% in 2020, then jumped by 99 bps to 936.0% in 2023.
Per Business Quant data, the three most recent Net Margin figures were 936.0% in Q1 2023, 130216.12% in Q4 2020, and 73918.76% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	15.02%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	34.53%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	20.17%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	30.33%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Palisade Bio	985.76	-132.63 Mn	-	-

Download Data